Gilead Sciences is writing a very expensive love letter to antibody drug conjugates, announcing on April 7, that it will acquire Munich-based Tubulis for $3.15 billion in upfront cash. The blockbuster buyout instantly shines a global spotlight on Tubulis’ small Cambridge outpost, even as the company’s core research engine stays rooted in Europe. The deal pulls Tubulis’ clinical-stage antibody drug conjugate programs into Gilead’s oncology portfolio, and local researchers and investors are now watching to see whether Gilead builds out the Cambridge presence or keeps most of the action around Tubulis’ Munich hub.
Deal details and timeline
Gilead will pay $3.15 billion in upfront consideration and could hand over as much as $1.85 billion more in contingent milestone payments, according to an EQT Life Sciences release. The transaction covers all outstanding Tubulis equity and is structured to be payable at closing on a cash-free, debt-free basis. It is expected to close in the second quarter of 2026, with Gilead planning to finance the purchase using a mix of cash on hand and senior unsecured notes, the announcement says. The Cambridge angle on the deal was first flagged by the Boston Business Journal.
What Tubulis builds
Headquartered near Munich, Tubulis develops next-generation antibody drug conjugates and has two lead programs that are already moving through early clinical testing. The company lists TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC, and TUB-030, a 5T4-targeted ADC, as its front-running candidates. Tubulis and industry reporting note that the firm closed a large Series C round last year as it geared up for a U.S. push. As part of that strategy, the company set up a Massachusetts presence at the Cambridge Innovation Center, where several executives have been based, industry reporting shows.
Why Cambridge matters
For Boston’s life-science ecosystem, the Tubulis deal is a reminder that even modest local footprints can pay off in a big way for European biotech. A lean Cambridge office can still plug a company into U.S. clinicians, investors, and academic partners, giving it credibility and visibility with global buyers. Local coverage highlighted Tubulis’ Cambridge ties as a key part of its U.S. strategy and exit potential, according to the Boston Business Journal. That presence helped position Tubulis as a company to watch for larger pharma players hunting for ADC assets.
Gilead’s strategy
Gilead has been steadily bulking up its oncology footprint through collaborations and acquisitions, and this is not the first time the company has circled Tubulis. The two companies previously announced an option and license agreement in December 2024, company materials show, giving Gilead an early look under the hood at Tubulis’ platform. EQT Life Sciences said Tubulis will now operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for continued ADC innovation.
The acquisition underscores that investor and pharma appetite for ADC platforms is still running hot after a run of sizable financings and partnership deals in recent years, industry coverage shows. Regulators, investors, and local stakeholders in Massachusetts and Germany will be watching how Gilead divides the work between Munich and the Cambridge outpost as the transaction moves toward its expected closing this quarter.
